Chronic Eosinophilic Leukemia (DBCOND0029592)

Identifiers

Synonyms

Chronic Eosinophilic Leukemia (CEL) / Chronic eosinophilic leukaemia / Chronic eosinophilic leukemia / Chronic eosinophilic leukemia (disorder) / Chronic eosinophilic leukemia (morphologic abnormality)

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Imatinib	A tyrosine kinase inhibitor used to treat a number of leukemias, myelodysplastic/myeloproliferative disease, systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors.	Platelet-derived growth factor receptor betatarget Tyrosine-protein kinase ABL1target Mast/stem cell growth factor receptor Kittarget Proto-oncogene tyrosine-protein kinase receptor Rettarget High affinity nerve growth factor receptortarget Macrophage colony-stimulating factor 1 receptortarget Platelet-derived growth factor receptor alphatarget Epithelial discoidin domain-containing receptor 1target Cytochrome P450 3A4enzyme Breakpoint cluster region proteintarget Cytochrome P450 1A2enzyme Cytochrome P450 2D6enzyme Cytochrome P450 2C9enzyme Cytochrome P450 2C19enzyme Cytochrome P450 3A5enzyme Cytochrome P450 3A7enzyme Solute carrier family 22 member 1transporter ATP-dependent translocase ABCB1transporter Solute carrier family 22 member 2transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Phospholipid-transporting ATPase ABCA3transporter Albumincarrier Alpha-1-acid glycoprotein 1carrier Bile salt export pumptransporter Cytochrome P450 2C8enzyme ATP-binding cassette sub-family C member 2transporter Multidrug resistance-associated protein 1transporter Organic cation/carnitine transporter 2transporter Solute carrier organic anion transporter family member 1B3transporter ATP-binding cassette sub-family C member 4transporter Solute carrier organic anion transporter family member 1A2transporter Discoidin domain-containing receptor 2target Induced myeloid leukemia cell differentiation protein Mcl-1target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT00276926	Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias	Imatinib	Not Available	2	unknown_status
NCT00489203	Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer	Beclomethasone dipropionate Methotrexate Tacrolimus	supportive_care	2	completed
NCT01233921	Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer	Palifermin	supportive_care	Not Available	completed
NCT00787384	Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes	Imatinib	treatment	2	completed
NCT00890747	Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy	Sunitinib	treatment	1	completed
NCT01558778	Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	Not Available	withdrawn
NCT01484015	Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia	Cefepime	treatment	1	completed
NCT00025415	Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction	Imatinib	treatment	1	completed
NCT01305200	Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant	Calcium Phosphate	supportive_care	3	completed
NCT01384513	A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies	Busulfan Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT01199562	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant	Foscarnet Ganciclovir Valganciclovir	Not Available	Not Available	completed
NCT01159067	Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload	Deferasirox	supportive_care	2	terminated
NCT00408681	Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant	Lithium carbonate	supportive_care	Not Available	completed
NCT00357305	Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders	Cytarabine Etoposide Vorinostat	treatment	1	completed
NCT00799461	Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications	No drug interventions	supportive_care	3	completed
NCT00112593	Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	Not Available	completed
NCT00856388	Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Fludarabine Melphalan	treatment	Not Available	completed
NCT01588015	Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	1	completed
NCT01231919	MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia	No drug interventions	treatment	1	completed
NCT01053494	Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer	No drug interventions	supportive_care	Not Available	completed
NCT00795769	Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant	Ondansetron	supportive_care	2	completed
NCT00381550	3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia	Fludarabine Triapine	treatment	2	completed